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The paraoxonase 1 codon 192 R allele has been previously reported to have a role in successful
aging. The relationship between PON1 genotypes, enzymatic activity, and mass concentration
was evaluated in a group of 229 participants from 22 to 104 years of age, focusing our attention
on nonagenarian/centenarian participants. We found a genetic control for paraoxonase activity
that is maintained throughout life, also in the nonagenarians/centenarians. This activity decreases
significantly during aging and shows different mean values among R and M carriers, where Rþ
and M carriers have the significant highest paraoxonase activity. Results from the multinomial
regression logistic model show that paraoxonase activity as well as Rþ and M carriers con-
tribute significantly to the explanation of the longevity phenotype. In conclusion, we show that
genetic variability at the PON1 locus is related to paraoxonase activity throughout life, and
suggest that both parameters affect survival at extreme advanced age.
THE paraoxonase gene family contains at least threemembers, named PON1, PON2, and PON3, which are
located on chromosome 7q21.3-22.1 (1). This enzyme is a
high-density lipoprotein (HDL)–bound arylesterase which
hydrolyzes lipoperoxides. It is responsible for the protective
effects of HDL on LDL (low-density lipoprotein) perox-
idation (2,3). Oxidized LDL are pro-inflammatory, pro-
atherogenic, and responsible for several phenomena such as
foam cell production, cytotoxic effects toward arterial wall
cells, and macrophagic cytokine induction. Inter-individual
variability of PON1 serum activity has been thought to play
an important modulatory role in the risk of developing
atherosclerosis (4).
PON1 gene polymorphisms lead to an amino acid sub-
stitution (Gln-Arg) at position 192 in the coding region of
the gene and to an amino acid substitution (Leu-Met) at
position 55. Alleles at codon 192 (Q and R alleles) and
codon 55 (L and M alleles) in the PON1 locus have been
associated with enzymatic activity and concentration,
respectively (5–7). There is wide variation in PON1 protein
and activity between individuals even within genotype
groups (8). In addition to genetic polymorphisms, PON1
activity can be modified by several factors such as diet,
lifestyle, and pathologic states (9). Consistently, a large
number of studies suggested an association between major
cardiovascular diseases and the Arg 192 (commonly
indicated as allele R) variant (10). Also the Leu 55 variant
(currently named as allele L) has been associated with
cardiovascular disease susceptibility (11). It has also been
suggested that the codon 192 R allele does not exert any
significant role on CHD (coronary heart disease) risk in an
Italian population (12). In contrast, data indicated that the
PON1 genotype affects the responsiveness of vasculature
to triglycerides (13). It is likely to be the phenotype and
not simply the genotype that is important in the interaction of
PON1 with CHD (14,15). The relatively small number of
studies taking into consideration PON1 concentration and/or
activity data has suggested that PON1 levels are reduced in
CHD, and that this effect is independent of PON1 genotype
(16). Until now, few studies have investigated the possible
role of PON1 variability and survival at extreme advanced
age. Our previous papers reported an increase in the
frequencies of R allele and Rþ carriers both in Irish octo/
nonagenarians and Italian centenarians in comparison with
their younger controls (17,18). We have supposed that the R
allele could decrease mortality in carriers and that
centenarians could have a genetically determined para-
oxonase activity advantageous for longevity (19). At
present, the role of PON1 genotypes and phenotypes in
aged people free of disease has not been properly
investigated.
In this study we wanted to better explore the role of
PON1 during aging, especially focusing our attention on
nonagenarians/centenarians, individuals who have reached
the extreme limits of human life span. A sample of 229
participants from 22 to 104 years of age was divided into
three different subgroups (young, elderly, and nonagenarians/
centenarians as reference group) and PON1 genotypes,
paraoxonase activity, arylesterase activity, and paraoxonase
mass concentration were evaluated to define the role of these
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variables in the chance for young and elderly people to be-
come extremely old.
METHODS
Participants
A sample of 77 young participants ranging from 22 to
65 years of age, 56 elderly participants ranging from 66 to
89 years of age, and 96 nonagenarian/centenarian partic-
ipants were enrolled. All the participants were genetically
unrelated, recruited in Central Italy, and appeared healthy at
the time of blood collection, as assessed by clinical exami-
nation and recent clinical history (20). In particular, cen-
tenarians belonged to category A and B of our previous
classification (21); those in category C were excluded from
this study. Inclusion criteria for category A were the fol-
lows: absence of physical disabilities (Activities of Daily
Living [ADL]¼A, B, or C; Instrumental Activities of Daily
Living [IADL] . 4), absence of severe cognitive impair-
ment (Mini Mental State Examination [MMSE] . 20),
absence of clinically evidence of cancer, absence of severe
renal failure, absence of severe anemia, and absence of
severe liver disease. Inclusion criteria for category C were as
follows: presence of severe cognitive impairment (MMSE
, 12), presence of severe physical impairment (ADL ¼ F–
G; IADL¼0), presence of overt cancer, presence of anemia,
presence of severe liver diseases, and presence of renal
insufficiency. Category B included the centenarians whose
health conditions were intermediate between those of cate-
gories A and C. All the volunteers were informed about the
goal of the study and gave informed, written consent.
PON1 192 and 55 Genotyping
DNA was extracted from blood lymphocytes by the
salting-out method (22). Polymerase chain reaction was
performed using primer sequences derived from published
data and specific for the amplification of the region sur-
rounding codons 192 and 55. The amplification reactions
and methodologies have been previously described (17).
Biochemical Profile of Recruited Participants
Serum concentration of the main parameters of lipo-
metabolic balance (fasting glucose, total cholesterol, HDL
cholesterol, and triglyceride levels) was measured using
commercially available kits on a Roche/Hitachi 912 (Roche
Diagnostics, Basel, Switzerland), according to the manu-
facturer’s specifications, and quality control was within the
recommended precision for each test.
Paraoxonase Activity, Arylesterase Activity,
Paraoxonase Mass Concentration,
and Specific Activity
Paraoxonase activity was measured by adding serum to
a buffer containing paraoxon (o,o-diethyl-o-p-nitrophenyl-
phosphate; Sigma-Aldrich, Milan, Italy). The rate of gener-
ation of p-nitrophenol was measured at 405 nm with the
use of a spectrophotometer (Beckman Du-640; Beckman
Coulter, Inc., Fullerton, CA) (23). Arylesterase activity in
serum was measured as above using phenylacetate as
substrate and setting the spectrophotometer at 270 nm (24).
Serum concentration of paraoxonase was assayed by
a competitive enzyme-linked immunoassay (25). Specific
activity was determined as U/lg with paraoxon as substrate.
Statistical Analysis
Data were analyzed with the SPSS/Win program (version
11.5; SPSS Inc., Chicago, IL). Triglycerides and paraoxonase
activity were natural log transformed before statistical
analyses to achieve a normal distribution. The corresponding
results are shown as geometric means3/4 antilog standard
deviation (SD). Differences among the three age groups
(young, elderly, and nonagenarians/centenarians) were ini-
tially assessed by univariate analysis using the analysis of
variance (ANOVA) test for continuous variables and the v2
test for categorical variables. The distributions of the PON1
192 and PON1 55 genotypes and allele frequencies in the
two groups were compared by v2 test. Hardy–Weinberg equi-
librium was checked by Monte Carlo Markov Chain (26).
Multinomial Logistic Regression Model
Because age is defined as a three-level categorical out-
come, the multinomial logistic regression was performed to
evaluate multivariate relationships between the classified age
and a set of covariates (carrier192, carrier55, sex, arylester-
ase activity, paraoxonase mass concentration, paraoxonase
activity). Arylesterase activity, paraoxonase mass concen-
tration, and paraoxonase activity were continuous covar-
iates, and they showed the relative strength of association
with the outcome in the regression model. After the deletion
of two cases with missing values, data from 227 people were
available for the analysis and the multinomial logistic
regression generated two logit functions for assessing
prediction of people in one of three categories of outcome.
Odds ratios (ORs) were estimated for the young and elderly
groups with respect to the nonagenarian/centenarian group
(reference group) (27). Bonferroni’s correction was used to
compensate for inflated type I error rate with six predictors.
The corrected value for a¼ 0.008 was obtained by dividing
a ¼ 0.05 by the number of predictors (n¼ 6).
RESULTS
Table 1 shows the demographic, biochemical, and clinical
characteristics of the participants divided by age groups. In
the nonagenarian/centenarian group, there was a significant
overrepresentation of females with respect to the other two
groups, as expected from the higher survival of females in
the extreme decades of life in Italy as well as in other
countries (21,28). Body mass index, paraoxonase activity,
arylesterase activity, and paraoxonase specific activity were
significantly lower in nonagenarians/centenarians compared
to elderly and young individuals. Body mass index and
arylesterase activity were also different between elderly and
young people. Paraoxonase mass concentration followed
a different pattern as it was similar in young people and
nonagenarians/centenarians, showing a significant decrease
in elderly persons. HDL cholesterol and triglyceride levels
were similar in elderly people and in nonagenarians/cente-
narians, but were higher in these two groups than in the
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group of young people. It was interesting to note that total
cholesterol levels were similar in the young people and
nonagenarians/centenarians but significantly lower in these
two groups than in the elderly people.
All the participants were also genotyped for PON1 192 and
55 polymorphisms. In all the groups, the observed genotypes
were in agreement with those expected at Hardy–Weinberg
equilibrium (p . .05). The genotypes were grouped as Rþ
carriers (QRþRR) and R carriers (QQ) for the codon 192
polymorphism, and as Mþ carriers (LMþMM) and M
carriers (LL) for the codon 55 polymorphism. A trend to-
ward a higher frequency of PON1 192 Rþ carriers, though
not statistically significant, was found in the elderly and
nonagenarian/centenarian groups (44.2% for young, 55.4%
for elderly, and 53.1% for nonagenarian/centenarian partic-
ipants), whereas no difference was found between young
people and nonagenarians/centenarians for PON1 55 Mþ
carrier frequencies (61.0% for young, 73.2% for elderly, and
61.5% for nonagenarian/centenarian participants).
In Tables 2 and 3, the mean values of paraoxonase activity,
arylesterase activity, paraoxonase mass concentration, para-
oxonase specific activity, and HDL in the three age groups
were reported and subdivided according to PON1 Rþand R
carriers (codon 192) and Mþ and M carriers (codon 55).
Paraoxonase activity was significantly decreased with age
both in R and M carriers, and the major decrease was pres-
ent in the nonagenarian/centenarian group. We also found,
in the last age group, a genetic control for paraoxonase
activity that was maintained throughout life. As shown in
Figure 1, the Rþ and M carriers had the highest levels of
paraoxonase activity throughout the entire age-range.
Arylesterase activity also decreased significantly in the
three age groups for both carriers. The higher decrease was
already evident in the elderly group, independently of the
polymorphisms. The different levels of arylesterase activity
correlate only among M carriers, with Mþ participants
having the lower levels. Moreover, ANOVA showed an in-
teraction between M carriers and age groups on arylesterase
activity (Table 3).
Paraoxonase mass concentration was dependent on age
group, with the lowest levels in the elderly group. No dif-
ferences in paraoxonase mass concentration among R and M
Table 1. General Characteristics of the Studied Participants
Characteristic
Young
(22–65 y) N ¼ 77
Elderly
(66–89 y) N ¼ 56
Nonagenarians/Centenarians
(90 y) N ¼ 96
Age, y 43.8 6 12.9 75.5 6 5.6 98.4 6 5.6
Sex (M %) (M/F) 51.9 (40/37)* 46.4 (26/30)y 15.6 (15/81)
BMI, kg/m2 24.4 6 1.3*z 26.6 6 4.1y 23.1 6 3.9
Fasting glucose, mmol/L 4.96 6 0.33 5.44 6 1.17y 4.93 6 1.65
Total cholesterol, mmol/L 5.09 6 1.04 5.91 6 0.78y 5.06 6 1.13
Triglycerides, mmol/L 0.82 3/4 0.02* 1.15 3/4 0.02 1.09 3/4 0.02
HDL cholesterol, mmol/L 1.29 6 0.30* 1.43 6 0.40 1.47 6 0.43
PON activity, U/ml 292.95 3/4 1.65* 297.14 3/4 1.65y 198.76 3/4 1.82
Arylesterase activity, U/ml 87.5 6 39.2*z 56.4 6 16.5y 45.2 6 15.7
PON mass concentration, lg/ml 103.2 6 24.9 93.4 6 20.0y 104.4 6 28.2
PON specific activity, U/lg 3.4 6 2.0* 3.8 6 2.3y 2.4 6 1.5
Note: Values are arithmetic means 6 standard deviation (SD), geometric means3/4 antilog SD for skewed data.
p , .05 for the following comparisons: *Nonagenarians/centenarians vs Young; yNonagenarians/Centenarians vs Elderly; zElderly vs Young.
M¼ male; F¼ female; BMI ¼ body mass index; HDL¼ high-density lipoprotein.
Table 2. Analysis of Variance in the Three Age Groups by PON1 Carrier192
Age Carrier192
Paraoxonase
Activity
(U/ml)
Arylesterase
Activity
(U/ml)
Paraoxonase
Mass
Concentration
(lg/ml)
Paraoxonase
Specific
Activity
(U/lg)
HDL
Cholesterol
Levels
(mmol/L)
20–65 y R (n ¼ 43) 194.0 6 1.4 84.8 6 39.5 101.6 6 26.6 2.0 6 0.4 1.27 6 0.31
Rþ (n ¼ 34) 493.4 6 1.3 90.7 6 39.2 105.1 6 22.9 5.1 6 1.9 1.31 6 0.28
66–89 y R (n ¼ 25) 205.7 6 1.4 52.5 6 10.8 93.1 6 19.3 2.4 6 1.0 1.44 6 0.38
Rþ (n ¼ 31) 399.7 6 1.5 59.7 6 19.4 93.4 6 20.0 4.9 6 2.4 1.42 6 0.43
90 y R (n ¼ 45) 131.72 6 1.6 46.5 6 17.5 103.5 6 25.8 1.5 6 0.9 1.56 6 0.47
Rþ (n ¼ 51) 287.0 6 1.4 43.8 6 14.2 103.9 6 29.2 3.2 6 1.5 1.39 6 0.39
Total R (n ¼ 113) 168.4 6 1.6 62.4 6 32.3 100.5 6 25.0 1.9 6 0.9 1.42 6 0.41
Rþ (n ¼ 116) 367.6 6 1.5 43.8 6 14.2 101.5 6 25.6 4.2 6 2.1 1.37 6 0.37
Analysis of variance F value F value F value F value F value
Age 38.97* 57.21* 3.43y 20.00* 5.18*
Carrier192 250.44* 0.92 0.19 141.17* 0.94
Age by carrier192 2.23 0.83 0.09 5.15* 1.48
Note: Values are means 6 standard deviation.
*p , .01.
yp , .05.
HDL¼ high-density lipoprotein.
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carriers were found. Moreover, we found that age groups
and M carriers interact on paraoxonase mass concentration
(Table 3). Mean values of paraoxonase mass showed a
different trend in M carriers with respect to Mþ carriers; in
the former, we found the lowest levels in the elderly groups,
whereas in the latter, we found the highest levels in the
nonagenarian/centenarian group.
Mean values of paraoxonase specific activity significantly
decreased in the three age groups. In particular, the more
evident decrease was present in the nonagenarian/centenarian
group. Paraoxonase specific activity showed a genetic control
that was maintained throughout life, also in the oldest age
group. This specific activity showed different values among
R and M carriers, where Rþ carriers and M carriers had the
highest values. ANOVA highlighted that age groups and R
carriers interact on paraoxonase specific activity (Table 2).
To investigate whether the evaluated parameters were
related to the achievement of extreme age, we made use of
a multinomial logistic regression model. We decided to
evaluate the results obtained from the model by using
a conservative approach; therefore, we considered statisti-
cally significant p , .008 as obtained from the Bonferroni
correction (see Methods). The multinomial logistic regres-
sion model provided significant likelihood ratio test results
for each predictor, except for paraoxonase mass concentra-
tion (2LR¼335.71, p¼ .082), and verified that the ORs for
both comparisons are simultaneously different from zero.
There was good model fit on the basis of six predictors using
a Pearson criterion (v2¼ 402.87, p¼ .897). Comparison of
log-likelihood ratios for models with only the intercept and
with the predictors showed reliable improvement (v2 ¼
330.71, p , .0001). Individual 95% confidence intervals
(95% CI) are presented for each estimated OR value. The
results of this analysis are shown in Table 4, in which the OR
values (95% CI) for the variables introduced in the model are
reported. In the top portion of Table 4, the comparison
between the young group versus the nonagenarian/centenar-
ian group (reference group) is reported. The continuous
variables (arylesterase and paraoxonase activities) fitted
significantly in the model and they contributed to explain
the variability, that is, the longevity. Moreover, as expected
in our model, females had an advantage in achieving the
extreme limits of human life span (OR, 5.93; 95% CI, 2.33–
15.12; p , .001). Concerning the relationship between the
different carriers and the probability of young people to
become centenarians, we found that Rþ carrier and M
carrier participants were not significantly associated. Also,
paraoxonase mass concentration did not reach statistical
significance; thus, its role in longevity is likely negligible.
In the bottom portion of Table 4, the comparison between
the elderly group versus the nonagenarian/centenarian group
(reference group) is reported. In this case, paraoxonase ac-
tivity was significantly associated with longevity (OR, 1.01;
95% CI, 1.01–1.02; p, .001). Regarding the involvement of
Rþ and Mcarriers and their relationship with longevity, we
found that Rþ carrier and M carriers elderly participants
have an advantage to become centenarians with ORs of
6.25 (95% CI, 1.71–22.91; p ¼ .006) and 4.60 (95% CI,
1.67–12.64; p¼ .003), respectively. The advantage of females
was confirmed (OR, 4.11; 95% CI, 1.68–10.8; p¼ .002). On
the contrary, arylesterase activity and paraoxonase mass con-
centration were not significantly associated with longevity.
DISCUSSION
Recently, the genotypic analysis of healthy Italian
centenarians and Northern Ireland nonagenarians has pro-
vided evidence that PON1 genotypes at the 192 locus, in
particular Rþ carriers, were found significantly increased in
the oldest old compared to young people. This evidence sup-
ports the hypothesis that the PON1 192 variant was involved
in the definition of the longevity phenotype (17,18).
In the present study, the genetic analysis of the PON1
192 variant showed evidence of a trend toward a higher fre-
quency of PON1 192 Rþ carriers in elderly persons and in
nonagenarians/centenarians with respect to young people.
This result is in agreement with the above mentioned data,
except for the lack of statistical significance, probably due to
the smaller sample size in comparison to the previous study
Table 3. Analysis of Variance in the Three Age Groups by PON1 Carrier55
Age Carrier55
Paraoxonase
Activity
(U/ml)
Arylesterase
Activity
(U/ml)
Paraoxonase
Mass
Concentration
(lg/ml)
Paraoxonase
Specific
Activity
(U/lg)
HDL
Cholesterol
Levels
(mmol/L)
20–65 y M (n ¼ 30) 431.2 6 1.6 103.6 6 41.0 114.6 6 21.6 4.4 6 2.4 1.34 6 0.31
Mþ (n ¼ 47) 228.9 6 1.6 77.2 6 34.6 103.2 6 24.9 2.8 6 1.5 1.25 6 0.29
66–89 y M (n ¼ 15) 421.0 6 1.6 58.3 6 17.8 89.6 6 21.2 5.5 6 2.9 1.45 6 0.54
Mþ (n ¼ 41) 261.6 6 1.6 55.7 6 16.2 94.8 6 19.6 3.2 6 1.7 1.42 6 0.35
90 y M (n ¼ 37) 256.8 6 1.5 53.7 6 14.0 100.2 6 27.6 3.0 6 1.6 1.48 6 0.36
Mþ (n ¼ 59) 169.9 6 1.8 45.1 6 15.8 105.9 6 27.4 2.0 6 1.3 1.46 6 0.43
Total M (n ¼ 82) 339.8 6 1.7 72.8 6 36.1 103.5 6 25.9 4.0 6 2.3 1.42 6 0.42
Mþ (n ¼ 147) 210.8 6 1.7 56.2 6 28.2 99.7 6 24.9 2.6 6 1.5 1.38 6 0.38
Analysis of variance F value F value F value F value F value
Age 19.76* 64.41* 4.19y 17.26* 4.36y
Carrier55 50.82* 15.43* 0.54 41.80* 0.69
Age by carrier55 1.05 3.21y 5.89* 1.97 0.19
Note: Values are means 6 standard deviation.
*p , .01.
yp , .05.
HDL¼ high-density lipoprotein.
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and for the results regarding the elderly group not evaluated
in the previous work (17). The main purpose of the present
study was to evaluate the relationship between genetic
variants of paraoxonase and its phenotype during aging.
The first new finding of this work was the maintenance
throughout life and especially in nonagenarians/centenarians
of the tight correlation between the genetic variability of
the PON1 gene and the enzyme activity of the gene product.
In particular, Rþ and M carriers maintained significantly
higher paraoxonase activity levels than did the R and Mþ
carriers. This genetic control of enzymatic activity was
found by several authors (5,29,30). In their studies, the cor-
relation between phenotype and genotype was investigated
in middle-aged people and did not include the oldest old,
that is, the group of participants that we have taken into con-
sideration in the present study. The maintenance of the ge-
netic control in extreme advanced age is an interesting
phenomenon that we have already described for interleukin-
6 protein in centenarians (31,32).
The second interesting result of this work was the de-
crease during aging of paraoxonase and arylesterase activ-
ities. For the paraoxonase activity the major decay was
present in the nonagenarian/centenarian group, whereas the
arylesterase activity started to decrease in the elderly group.
Recently, Seres and colleagues (33) found a negative and
significant correlation between PON1 activity and age. We
confirmed their results for paraoxonase activity extending
our study also to nonagenarians/centenarians. The loss of
the enzymatic activity during aging is not an uncommon
phenomenon that involves several biological enzymes. In
particular, the inactivation of paraoxonase enzyme activity
has been attributed to the presence of lipid peroxides (34,35)
and to the increase of oxidative stress with age. The data
presented here suggest that the decrease of PON1 enzymatic
activity is correlated to an alteration of the PON1 protein
rather than to a reduction in its production.
The results of the multinomial logistic regression analysis
suggest that the enzymatic activity toward paraoxon is the
major variable that describes the model and has a central role
throughout life. In fact, the analysis indicates that paraoxon-
ase activity contributes substantially to determining longevity
when we compared the young group versus the nonagenar-
ians/centenarians as well as the elderly group versus the
nonagenarians/centenarians. Accordingly, we can hypothe-
size that a high paraoxonase activity, genetically determined
by PON1 192 Rþ carriers and PON1 55 M carriers, could
offer a cumulative benefit starting from a young age and
becoming important in reaching the extreme limits of human
life span. The significant role of Rþ and M carriers in the
contribution to the longevity phenotype only in the last part
of the life originated from the choice of a conservative
multinomial logistic regression analysis. This model suggests
that genetic variability contributes mostly to determining
a phenotype characterized by a high paraoxonase activity. A
recent study on the three-dimensional structure of the enzyme
has evidenced that the amino acid R192 was an important
active-site residue. This peculiar feature might justify the
alterations in the enzymatic activity; thus, it might explain the
genotype-dependent variation observed in our study (36).
In previous studies, Jarvik and colleagues (14) and
Mackness and colleagues (16), independently, have also
Figure 1. Mean values of paraoxonase activity among R (top) and M (bottom)
carriers in the three age groups.
Table 4. Multinomial Logistic Regression Model for Age Groups
Age Covariates OR (95% CI) p Value
Young Arylesterase activity 1.06 (1.03–1.09) ,.001*
Paraoxonase mass concentration 0.99 (0.97–1.01) .264
Paraoxonase activity 1.01 (1.00–1.01) .008*
Carrier192 (R) 1.00 (Reference)
Carrier192 (Rþ) 5.74 (1.43–23.02) .014
Carrier55 (Mþ) 1.00 (Reference)
Carrier55 (M) 3.08 (1.13–8.34) .027
Sex (M) 1.00 (Reference)
Sex (F) 5.93 (2.33–15.12) ,.001*
Elderly Arylesterase activity 1.01 (0.98–1.04) .432
Paraoxonase mass concentration 0.98 (0.97–1.00) .030
Paraoxonase activity 1.01 (1.01–1.02) ,.001*
Carrier192 (R) 1.00 (Reference)
Carrier192 (Rþ) 6.25 (1.71–22.91) .006*
Carrier55 (Mþ) 1.00 (Reference)
Carrier55 (M) 4.60 (1.67–12.64) .003*
Sex (M) 1.00 (Reference)
Sex (F) 4.11 (1.68–10.8) .002*
Note: Nonagenarians/centenarians were the comparison group.
*Level of significance a , .008 is considered significant (see Multinomial
logistic regression model).
OR ¼ odds ratio; CI ¼ confidence interval.
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found that paraoxonase activity is a better predictor of
cardiovascular disease than are PON1 192 and PON1 55
genotypes alone. In particular, they concluded that the
quality of the PON1 enzyme was more important than the
genetics of the PON1 gene. Here, we show that PON1
activity and genetics are deeply interconnected throughout
life and that both play a role in human longevity.
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